News Takeda finalises buyout of TiGenix Japanese pharma giant Takeda has completed its buyout of TiGenix.
News Takeda to buy stem cell specialists TiGenix for $626m Decision follows EU regulators' decision to back Crohn's stem cell therapy
News First ever 'off the shelf' stem cell therapy nears European ... Alofisel recommended for complex perianal fistulas in Crohn's disease
News Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
